Collaborative Effort for a Centralized Worldwide Tuberculosis Relational Sequencing Data Platform

Clinical Infectious Diseases

Volumn 61, Issue , 2015, Pages S141-S146

  Starks, Angela M ^a   Aviles, Enrique ^b   Cirillo, Daniela M ^c   Denkinger, Claudia M ^d   Dolinger, David L ^d   Emerson, Claudia ^e   Gallarda, Jim ^f   Hanna, Debra ^b   Kim, Peter S ^g   Liwski, Richard ^b   Miotto, Paolo ^c   Schito, Marco ^b   Zignol, Matteo ^h  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b CRITICAL PATH INSTITUTE   (United States)

^c SAN RAFFAELE HOSPITAL   (Italy)

^d FOUNDATION FOR INNOVATIVE NEW DIAGNOSTICS   (Switzerland)

^e ST MICHAEL'S HOSPITAL   (Canada)

^f BILL AND MELINDA GATES FOUNDATION   (United States)

^g NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^h WORLD HEALTH ORGANIZATION   (Switzerland)

Author keywords

database; drug resistance; Mycobacterium tuberculosis

Indexed keywords

ARTICLE; CLINICAL DECISION MAKING; CLINICAL LABORATORY; CLINICAL STUDY; DRUG SENSITIVITY; FEEDBACK SYSTEM; GENOTYPE; HUMAN; INFORMATION PROCESSING; ORGANIZATION; PHENOTYPE; PRIORITY JOURNAL; PUBLIC HEALTH; TUBERCULOSIS; TUBERCULOSIS RELATIONAL SEQUENCING DATA PLATFORM; ANTIBIOTIC RESISTANCE; DNA SEQUENCE; DRUG EFFECTS; GENETICS; INTERNATIONAL COOPERATION; MUTATION; MYCOBACTERIUM TUBERCULOSIS; NUCLEIC ACID DATABASE;

BACTERIAL DNA; TUBERCULOSTATIC AGENT;

ANTITUBERCULAR AGENTS; DATABASES, NUCLEIC ACID; DNA, BACTERIAL; DRUG RESISTANCE, BACTERIAL; GENOTYPE; HUMANS; INTERNATIONAL COOPERATION; MUTATION; MYCOBACTERIUM TUBERCULOSIS; SEQUENCE ANALYSIS, DNA; TUBERCULOSIS;

EID: 84943411464     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/civ610     Document Type: Article

References (27)

1. World Health Organization. Global tuberculosis report 2014. Geneva, Switzerland: WHO, 2014. WHO/HTM/TB/2014.08.
2. International Union Against Tuberculosis and Lung Disease. Guidelines for clinical and operational management of drug-resistant tuberculosis. Paris, France: International Union Against Tuberculosis and Lung Disease, 2013.
3. Dheda K,Warren RM, Zumla A, GrobuschMP. Extensively drug-resistant tuberculosis: epidemiology and management challenges. Infect Dis Clin North Am 2010; 24:705-25.
4. Gandhi NR,Weissman D, Moodley P, et al. Nosocomial transmission of extensively drug-resistant tuberculosis in a rural hospital in South Africa. J Infect Dis 2013; 207:9-17.
5. Wang F, Shao L, Fan X, et al. Evolution and transmission patterns of extensively drug-resistant tuberculosis in China. Antimicrob Agents Chemother 2014; 59:818-25.
6. Shah NS,Wright A, Bai GH, et al. Worldwide emergence of extensively drug-resistant tuberculosis. Emerg Infect Dis 2007; 13:380-7.
7. Sharma SK, Mohan A. Multidrug-resistant tuberculosis: a menace that threatens to destabilize tuberculosis control. Chest 2006; 130:261-72.
8. World Health Organization. WHO endorses new rapid tuberculosis test-a major milestone for global TB diagnosis and care. Geneva, Switzerland: WHO, 2010.
9. WorldHealth Organization. Molecular line probe assays for rapid screening of patients at risk of multidrug-resistant tuberculosis (MDR-TB)-policy statement. Geneva, Switzerland: WHO, 2008.
10. Gessler D, Dye C, Farmer P, et al. Public health. A national tuberculosis archive. Science 2006; 311:1245-6.
11. World Health Organization. Companion handbook to the WHO guidelines for the programmatic management of drug-resistant tuberculosis. Geneva, Switzerland: WHO, 2014.
12. Cohen T, Jenkins HE, Lu C, McLaughlin M, Floyd K, Zignol M. On the spread and control of MDR-TB epidemics: an examination of trends in anti-tuberculosis drug resistance surveillance data. Drug Resist Updat 2014; 17:105-23.
13. World Health Organization. Global strategy and targets for tuberculosis prevention, care and control after 2015. Report by the Secretariat. Geneva, Switzerland: WHO, 2013. WHA65/2012/REC/3.
14. Smith T, Wolff KA, Nguyen L. Molecular biology of drug resistance in Mycobacterium tuberculosis. Curr Top Microbiol Immunol 2013; 374:53-80.
15. Campbell PJ, Morlock GP, Sikes RD, et al. Molecular detection of mutations associated with first-and second-line drug resistance compared with conventional drug susceptibility testing of Mycobacterium tuberculosis. Antimicrob Agents Chemother 2011; 55:2032-41.
16. Heysell SK, Houpt ER. The future of molecular diagnostics for drugresistant tuberculosis. Expert Rev Mol Diagn 2012; 12:395-405.
17. Sandgren A, Strong M, Muthukrishnan P, Weiner BK, Church GM, Murray MB. Tuberculosis drug resistance mutation database. PLoS Med 2009; 6:e2.
18. Koser CU, Ellington MJ, Cartwright EJ, et al. Routine use of microbial whole genome sequencing in diagnostic and public health microbiology. PLoS Pathog 2012; 8:e1002824.
19. Koser CU, Bryant JM, Becq J, et al. Whole-genome sequencing for rapid susceptibility testing of M. tuberculosis. N Engl J Med 2013; 369:290-2.
20. Guio H, Tarazona D, Galarza M, Borda V, Curitomay R. Genome analysis of 17 extensively drug-resistant strains reveals new potential mutations for resistance. Genome Announc 2014; 2:e00759-14.
21. Merker M, Kohl TA, Roetzer A, et al. Whole genome sequencing reveals complex evolution patterns of multidrug-resistant Mycobacterium tuberculosis Beijing strains in patients. PLoS One 2013; 8: e82551.
22. Outhred AC, Jelfs P, Suliman B, et al. Added value of whole-genome sequencing for management of highly drug-resistant TB. J Antimicrob Chemother 2014; 70:1198-202.
23. Wattam AR, Abraham D, Dalay O, et al. PATRIC, the bacterial bioinformatics database and analysis resource. Nucleic Acids Res 2014; 42 (database issue):D581-91.
24. Flandrois JP, Lina G, Dumitrescu O. MUBII-TB-DB: a database of mutations associated with antibiotic resistance in Mycobacterium tuberculosis. BMC Bioinformatics 2014; 15:107.
25. Rhee SY, Gonzales MJ, Kantor R, Betts BJ, Ravela J, Shafer RW. Human immunodeficiency virus reverse transcriptase and protease sequence database. Nucleic Acids Res 2003; 31:298-303.
26. Shafer RW. Rationale and uses of a public HIV drug-resistance database. J Infect Dis 2006; 194(suppl 1):S51-8.
27. Critical Path to TB Drug Regimens. Tuberculosis therapeutic area supplement to the study data tabulation model user guide, 2012. Available at: http://www.cdisc.org/therapeutic#tuberculosis. Accessed 15 July 2015.